Retrospective Comparison of Chemotherapy-Induced Myelotoxicity in Patients with Ovarian Cancer Under and Over 60 Years of Age

Authors: Peintinger, F.; Georgoulopoulos, A.; Ralph, G.; Piswanger, C.

Source: Journal of Chemotherapy, Number 6, December 2006 , pp. 656-661(6)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

We examined whether women aged 60 years or older with ovarian cancer who were treated with surgery and postoperative chemotherapy are at higher risk of developing grade 4 hematological toxicity. Seventy-five patients were included: 34 patients aged <60 years (group I) were compared with 41 patients aged ≥60 years (group II) after postoperative treatment with single-agent carboplatin or carboplatin/taxane combination chemotherapy. Secondary prophylaxis with granulocyte colony-stimulating factors was performed to avoid dose reduction and chemotherapy delay. A total of 450 chemotherapy cycles was completed. Anemia and thrombocytopenia were mild in both groups. Overall, grade 4 neutropenia developed in 41% (group I) and in 49% (group II) (p=0.51). Febrile neutropenia occurred in 12% and 2%, respectively (p=0.17). The carboplatin/taxane combination was associated with grade 4 neutropenia in 42% (group I) and 58% (group II) (p=0.21). Women ≥60 years are not at higher risk of developing severe myelotoxicity than their younger counterparts, particularly after treatment with carboplatin/taxane combination chemotherapy.

Keywords: older patients; myelotoxicity; Ovarian cancer

Document Type: Research Article

Publication date: 2006-12-01

More about this publication?